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Background: The emergence of Zika virus (ZIKV) as an important cause of congenital and childhood develop-
mental disorders presents another challenge to global health. Efforts to develop a Zika vaccine have begun
although vaccine development against flaviviruses, of which ZIKV belongs to, has proven to be time-consum-
ing and challenging. Defining the vaccine attributes that elicit adaptive immune response necessary for pre-
venting ZIKV infection could provide an evidence-based guide to Zika vaccine development.
Methods: We used a previously described attenuated ZIKV DN-2 strain in a type-I interferon receptor defi-
cient mouse model and tested the hypothesis that duration of vaccine burden rather than peak level of infec-
tion, is a determinant of immunogenicity. We quantified both humoral and cellular responses against ZIKV
using plaque reduction neutralisation test and flow cytometry with ELISPOT assays, respectively. Vaccinated
mice were challenged with wild-type ZIKV (H/PF/2013 strain) to determine the level of protection against
infection.
Findings: We found that the overall vaccine burden is directly correlated with neutralising antibody titres.
Reduced duration of vaccine burden lowered neutralising antibody titres that resulted in subclinical infec-
tion, despite unchanged peak vaccine viraemia levels. We also found that sterilising immunity is dependant
on both neutralising antibody and CD8+ T cell responses; depletion of CD8+ T cells in vaccinated animals led
to wild-type ZIKV infection, especially in the male reproductive tract.
Interpretation: Our findings indicate that duration of attenuated virus vaccine burden is a determinant of
humoral and cellular immunity and also suggest that vaccines that elicit both arms of the adaptive immune
response are needed to fully prevent ZIKV transmission.
Funding: This study was supported by the National Medical Research Council through the Clinician-Scientist
Award (Senior Investigator) to E.E.O. Salary support for S.W. was from a Competitive Research Programme
grant awarded by the National Research Foundation of Singapore.
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Arthropod-transmitted flaviviruses are major global health scourges.
The prototypic flavivirus, yellow fever virus (YFV), periodically spills out
from the sylvatic transmission cycle to cause epidemics in Africa and
South America [1]. Dengue virus (DENV) causes an estimated 100 million
cases of acute disease annually [2]. The Japanese encephalitis (JE) sero-
complex group of viruses, including West Nile virus, cause occasionaloutbreaks of viral encephalitis in various parts of the world [3]. More
recently, the emergence of Zika virus (ZIKV) as a novel cause of congenital
and childhood developmental disorders adds to the conundrum [46].
As vector control to prevent flaviviral transmission has mostly proven to
lack sustainability and is ineffective, as is implemented in many coun-
tries, prevention of such flaviviral diseases will need to rely on effective
vaccines [7].
Flaviviral vaccine development has had mixed outcomes. The live
attenuated YF vaccine is arguably one of the best vaccines in the
world  a single dose elicits immunity that lasts for 10 years or more
Research in context
Evidence before this study
Vaccine development against flaviviruses such as Zika virus has
had mixed success despite the identification of numerous
potential candidates. A major limitation is a lack of detailed
understanding of the vaccine-inherent attributes that shape
the development of adaptive immunity against infection. Stud-
ies on the successful yellow fever live attenuated vaccine
(YF17D) have found that the magnitude of the innate immune
response as well as longer duration of vaccine burden corre-
lated with eventual neutralising antibody titre against yellow
fever virus. However, whether duration of vaccine burden func-
tionally determines vaccine immunogenicity and efficacy
remain to be determined.
Added value of this study
This study highlights the critical role of vaccine burden in the
development of adaptive immune responses against Zika virus
infection. The study also demonstrates in an A129 mouse model
that a successful Zika virus vaccine must elicit humoral and cel-
lular immunity in concert to confer sterilising immunity and
prevent Zika virus transmission.
Implications of all the available evidence
Our findings can guide the future development of vaccines
against Zika virus and other flaviviruses. Vaccine burden may
be useful as a determinant of immunogenicity, allowing for bet-
ter down-selection of potential candidates. Moreover, vaccines
that elicit both humoral and cellular immunity are needed to
prevent infection of certain organs such as the testes, highlight-
ing their possible necessity in preventing silent transmission
from vaccinated males to unvaccinated females.
2 C. Yau et al. / EBioMedicine 61 (2020) 111[8]. Likewise, both attenuated and inactivated vaccines against JEV as
well as the inactivated vaccine against tick-borne encephalitis have
also shown useful efficacy [9,10]. However, dengue vaccine develop-
ment has not been met with similar success. The only licensed den-
gue vaccine, Dengvaxia, was found to elicit imbalanced protection
against the four dengue virus serotypes. Moreover, Dengvaxia vacci-
nation in those without prior dengue infection also resulted in
increased risk of severe dengue [11,12]. Vaccine development against
ZIKV has proceeded, with at least two vaccine candidates having
completed phase 1 clinical trial [13,14]. However, whether these Zika
vaccine candidates will meet with similar success as YF vaccine or
present with problems that prevent widespread use, like Dengvaxia,
is uncertain as the properties that shape vaccine immunogenicity and
hence efficacy has remained undefined.
Studies on YF vaccine have found that vaccination activates the
innate immune response, including type-I interferon signalling, that
shape the magnitude of antibody response [15,16]. We have also
recently observed that viremia at day 7 but not day 3 post-vaccina-
tion correlated with neutralising antibody titres [17]. These findings
suggest that the duration rather than peak level of vaccine burden
determines shape vaccine-induced adaptive immunity. We tested
this suggestion using a previously reported attenuated ZIKV strain.
We found that truncation of vaccine burden in A129 type I interferon
receptor-deficient mice reduced both vaccine immunogenicity and
efficacy despite unchanged peak vaccine viremia [18]. With lowered
neutralising antibody titres from vaccine viremia truncation, chal-
lenge with wild-type ZIKV led to four-fold or greater boost inneutralising antibody titres; no antibody boosting was seen in ani-
mals with higher post-vaccination neutralising antibody titres. How-
ever, even unperturbed post-vaccination antibody titres were
insufficient to prevent ZIKV infection without cellular immunity.
Indeed, depletion of CD8+ T cells in vaccinated animals led to detect-
able infection in the testes and epididymis but not the central ner-
vous system upon wild-type ZIKV challenge. Our findings thus reveal
insights on live viral vaccine duration shapes adaptive immunity and




Wild-type H/PF/2013 ZIKV (KJ776791, from European Virus
Archive) was passaged on C6/36 cell line. Infectious clone of the
attenuated DN-2 was produced as described previously and the res-
cued virus was passaged in Vero cells but limited to 3 passages [18].
Sanger sequencing of PCR-amplified viral fragments was used to
ensure that no mutation was introduced to DN-2 in the course of in
vitro passaging. Sequence data was analysed using the Geneious soft-
ware and compared against an available wild-type ZIKV sequence
from NCBI (KJ776791). Viral titres were evaluated using plaque assay
as previously described [19].
2.2. Animals
All studies were performed in accordance with guidelines pro-
vided by the National Advisory Committee for Laboratory Animal
Research (NACLAR) in Singapore. All protocols in this study has been
approved by the Institutional Animal Care and Use Committee at Sin-
gapore Health Services (Protocol #2016/SHS/1197).
Type I IFN receptor-deficient 129 SvEv (A129) mice were pur-
chased from B&K Universal Ltd and housed in Duke-NUS Medical
School. Six to 12-week-old mice were used for all experiments. Litter-
mates were randomly assigned to each group.
Male mice were injected intraperitoneally (i.p.) with the indicated
dosages of virus in 200mL of PBS vehicle for DN-2 vaccination or H/
PF/2013 challenge. Serum was acquired through centrifugation of
submandibular blood collected on the specified days post-vaccina-
tion and challenge. Mice exhibiting a weight loss of greater than 20%
of original body weight or at experimental endpoint were sacrificed
via CO2 asphyxiation and cervical dislocation. At termination, animal
organs were harvested and stored at 80 °C.
2.3. Plaque reduction neutralization test
Plaque reduction neutralization test (PRNT) was performed on
BHK-21 cells as previously described [18]. Briefly, serial two-fold
dilutions were performed on serum samples after heat inactivation at
56 °C for 30 min. Serum dilutions were incubated with 40 pfu of H/
PF/2013 ZIKV for one hour at 37 °C in RPMI medium supplemented
with 2% foetal calf serum before inoculation onto BHK-21 cells. This
mixture was then removed after an hour of incubation at 37 °C upon
which 1% carboxymethyl cellulose overlay was added. Cells were
washed, fixed with 20% formalin and stained with 1% crystal violet
five days later. Viral plaques were then enumerated visually. Plaque
counts were plotted in a sigmoidal dose-response fit curve to calcu-
late PRNT50 values and presented as reciprocal values.
2.4. ELISA
To quantify anti-ZIKV IgG in mouse serum, MaxiSorpTM plates
(ThermoFisher Cat#44240421) were coated with 2£ 106 PFU of
H/PF/2013 ZIKV in coating buffer (79.5mg NaCO3+147mg NaHCO3 in
C. Yau et al. / EBioMedicine 61 (2020) 111 350mL H20; pH 9.6) overnight at 4 °C. Plates were blocked with 5%
BSA solution the following day for 2 h at room temperature. Mouse
serum was added and incubated for 1.5 h at room temperature. Anti-
ZIKV antibodies were then detected through the addition of HRP-
conjugated goat anti-mouse secondary antibodies (Dako Cat#P0447,
1:2000 in PBST). TMB substrate (KPL Cat#507600) was added for
7 min at room temperature in the dark before cessation of the reac-
tion with 1 N H2SO4. Plates were read at an absorbence of 450 nm
using a plate reader (Tecan Infinite M200) for quantification of anti-
ZIKV antibodies.
2.5. CD8+ T cell depletion
Optimization experiments were performed to determine the
appropriate dosages required to achieve CD8+ T cell depletions. A129
mice were administered intraperitoneally (i.p.) with anti-CD8a anti-
body (Bio X Cell #BE0061). A second antibody injection at the same
doses was given 2 days later, as previously described [20]. Flow
cytometry was performed one day after the second injection on sub-
mandibular blood stained with APC-conjugated anti-mouse CD3 (BD
Cat#565643) and BUV395-conjugated anti-mouse CD8b antibodies
(BD Cat#740278) to evaluate the optimal dose for successful CD8+ T
cell depletion.
For CD8 T-cell depletion, 10mg of anti-CD8a antibody diluted in
200mL PBS was injected i.p. at one and three days before challenge
with H/PF/2013. Successful depletion of CD8+ cells was confirmed via
flow cytometry.
2.6. Flow cytometry
Flow cytometry analysis was performed using the BD Fortessa and
FlowJo 10 software to evaluate depletion of CD8+ T cells after admin-
istration of anti-CD8a monoclonal antibodies. Whole blood was sub-
jected to red blood cell lysis using BD Pharm Lyse (BD Cat#555899)
and fluorescently labelled with a combination of conjugated anti-
B220 (BD Cat#557669), anti-CD3 (BD Cat#565643) and anti-CD8b
(BD Cat#740278) antibodies at 1:400 dilution for analysis.
Spleens from vaccinated mice were collected to evaluate B and
T cell populations in response to alterations to ZIKV DN-2 viraemia
duration. Briefly, spleens were passed through a 70mm cell
strainer to obtain a splenocyte suspension. The splenocytes were
then fluorescently labelled with conjugated anti-CD3, anti-CD8b,
anti-CD44 (BD Cat#560570) and anti-CD62L (BD Cat#563252)
antibodies at 1:400 dilution before subsequent analysis with the
BD Fortessa.
2.7. ELISPOT
CD8 magnetic positive selection was performed on splenocyte
suspensions acquired from vaccinated mice using CD8a (Ly-2)
Microbeads (Miltenyl Biotec 130117044) according to manufac-
turer’s instructions. Isolated CD8+ cells were added to 96-well plates
pre-coated with AN18 anti-mouse IFN-g antibodies (i-DNA
33213250) and stimulated with the ZIKV E294302 peptide
IGVSNRDFV (Mimotopes) or PMA/Ionomycin as previously described
[21]. Stimulations were performed in RPMI media overnight. Second-
ary biotnylated anti-IFNg antibodies (iDNA 33216250) were
added after stimulation followed by streptavidin. Spot-forming units
were then counted using ImmunoSpot S6 and analysed with the
accompanying software as per manufacturer’s protocol.
2.8. Viral rna extraction
Viral RNA was extracted from the serum acquired from subman-
dibular bleeds using the QIAamp Viral RNA Mini Kit (Qiagen Cat#
52906) according to manufacturer’s instructions. Harvested organswere homogenized with silica carbide using the FastPrep-24TM 5 G
instrument (MPBio). RNA was then extracted from the homogenate
using a TRIzol LS (ThermoFisher #10296010) and chloroform
method to induce phase separation. Organ RNA concentration was
measured using the NanoDrop 2000 Spectrophotometer (Thermo-
Fisher).2.9. qRT-PCR
ZIKV RNA levels in serum and organs were quantified using the
qScript One-Step RT-qPCR Kit (QuantaBio Cat# 96057-200) with
ZIKV 1086 and ZIKV 1162c primers with ZIKV 1107 probe ໿(50-6-
FAM- AGCCTACCTTGACAAGCAGTCAGACAC TCAA-30-BHQ-1 from
Integrated DNA Technologies) as described previously [18]. RNA
standards produced from in vitro transcription of primer and probe
target regions were used to generate a standard curve for quantifica-
tion. All qRT-PCR was performed and analysed using a LightCycler
480 RT-qPCR system (Roche) and LightCycler 480 software (Roche)
respectively.2.10. Nanostring analysis
Peripheral blood mononuclear cells (PBMCs) from A129 mice
were isolated from submandibular blood collected at days 0,1, and 3
post-challenge as previously described [19]. RNA was extracted from
PBMCs using the TRIzol and chloroform method described above.
50 ng of extracted RNA was then hybridized to the Nanostring
nCounter Mouse Immunology panel at 65 °C for 24 h. 50 ng of brain
or testes RNA extracted as described above was hybridized to the
NanoString nCounter Mouse Inflammation v2 panel (NanoString
Technologies) at 65 °C for 24 h.
Hybridized samples were quantified using the nCounter Sprint
profiler (NanoString Technologies). Data was analysed using the
nSolver Analysis Software (NanoString Technologies). Spearman cor-
relation analysis was performed to identify genes significantly corre-
lated with boosts in neutralising antibody titres. Subsequent
pathway analysis was performed using GO Enrichment analysis. Sig-
nificantly correlated pathways were clustered and summarized using
REVIGO as described previously [22].2.11. Statistical analyses
Unpaired t tests were performed for comparisons between data-
sets. Statistical significance was achieved if p-values were less than
0.05. All numerical data is presented as the mean § SD (standard
deviation). Graphs were generated with GraphPad Prism 8.3.1.
Correlation data was produced using nonparametric Spearman
correlation analysis in GraphPad Prism 8.3.1 with significance
achieved at p-values less than 0.05. Significantly correlated genes
were analysed against PANTHER classification system using Gene
Ontology (GO) Enrichment Analysis for biological processes with
Fisher’s exact test with FDR correction to identify significantly
enriched GO terms.2.12. Role of the funding source
This study was supported by the National Medical Research
Council through the Clinician-Scientist Award (Senior Investiga-
tor) to E.E.O. Salary support for S.W. was from a Competitive
Research Programme grant awarded by the National Research
Foundation of Singapore. The funding authorities were neither
involved in the conduct of these studies nor the preparation of
this manuscript.
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3.1. Truncation of DN-2 burden using a monoclonal antibody treatment
reduced anti-ZIKV neutralising antibody titres without affecting CD8+ T
cell responses
We have previously shown that inoculation of DN-2 in A129 mice
produced approximately 5 days of detectable viraemia [18]. This fea-
ture enabled us to use the area under the curve (AUC) of total dura-
tion of DN-2 viraemia as a surrogate measure of vaccine burden. To
investigate the impact of vaccine burden on immunogenicity and effi-
cacy in protection from wild-type virus infection, we capitalize on a
previously reported anti-ZIKV monoclonal antibody, ZAb_FLEP,
which targets a quaternary epitope near the ZIKV fusion loop to
reduce DN-2 vaccine burden [18,23,24]. Intraperitoneal ZAb_FLEP
treatment was instituted at days 3 and 6 after inoculation with DN-2,
during or after viraemia peak respectively. DN-2 vaccination without
ZAb-FLEP treatment and ZAb_FLEP only treatment served as controls
for the experiment (Fig. 1a). Indeed, ZAb_FLEP treatment at day 3
but not day 6 post-vaccination successfully reduced the duration of
both DN-2 viraemia and RNAemia compared to control mice without
reducing peak viraemia or RNAemia levels (Fig. 1b and 1c). RNAemia
was well-correlated to viremia levels, serving as an effective surro-
gate measurement (Supplementary Figure 1a). Area under the curve
(AUC) of RNAemia measured throughout the period of monitoring
was significantly decreased in mice that received ZAb_FLEP treat-
ment 3 days post infection compared to mice without ZAb_FLEP
treatment (Fig. 1d).
The impact of vaccine burden truncation on antibody response
was evaluated at 21 days post-vaccination. ZAb_FLEP treatment
at day 3 resulted in reduced antibody titre that neutralized 50%
of ZIKV on a plaque reduction neutralization test (PRNT50) com-
pared to either delayed or no ZAb-FLEP treatment (Fig. 1e).
Meanwhile, levels of anti-ZIKV IgG, as measured on an ELISA,
were unaffected (Fig. 1f). These findings suggest that greater vac-
cine burden in untreated mice could have led to greater levels of
affinity maturation in the B cells than mice with truncated DN-2
burden. Furthermore, significant positive correlation between
RNAemia AUC and neutralising antibody titres was observed
(Supplementary Figure 1b). No correlation, however, was found
between peak RNAemia and neutralising antibody titres (Supple-
mentary Figure 1c). These findings collectively suggest that the
total vaccine burden is important for shaping the quality of neu-
tralising antibody response.
We next investigated the impact of truncating DN-2 burden on
CD8+ T cell responses, which could also play important roles in con-
trolling ZIKV infection [25]. ZAb_FLEP was again administered to
truncate vaccine burden in assigned groups in a separate cohort of
A129 mice (Supplementary Figure 1d and 1e). Flow cytometry analy-
sis of splenocytes harvested 21 days post-vaccination revealed no
change in overall CD3+ or CD3+/CD8+T cell percentage (Supplemen-
tary Figure 1f and 1 g). The percentages of total central CD44+/
CD62L+central memory and CD44+/CD62L effector memory CD8+ T
cells were also unaffected DN-2 burden truncation (Figs. 1g and 1h,
Supplementary Figure 1 h). Quantification of antigen-specific CD8+ T
cells by stimulating splenocytes with a known immunodominant
ZIKV peptide epitope E294302 also revealed no significant difference
in IFN-g production in an ELISPOT assay (Fig. 1i) [21]. These findings
suggest that ZAb_FLEP treatment did not affect the development of
ZIKV antigen specific CD8+ T cells. This finding is consistent with a
recent clinical observation that antibodies neutralize extracellular
virions but are unable to eliminate infected cells that continue to
stimulate CD8+ T cell response through MHC class I antigen [26]. The
ZAb_FLEP treatment model thus allowed us to examine the role of
humoral immunity on ZIKV immunity without being confounded by
cellular immunity.3.2. Truncation of DN-2 burden resulted in loss of sterilising immunity
upon wild-type challenge
To determine how baseline neutralising antibody titres affect
immunity, we challenged these mice with a lethal 104 PFU (i.p.) dose
of the wild-type ZIKV (French Polynesian H/PF/2013 strain) (Fig. 2a)
[27]. Unvaccinated control animals all showed the expected wild-
type ZIKV viraemia that peaked at on day 2 post-challenge (Fig. 2b),
reduction in body weights (Fig. 2c) and 100% mortality rate (Fig. 2d).
Vaccinated animals, with or without DN-2 burden truncation, were
negative for wild-type ZIKV RNAemia except for one animal with
reduced DN-2 viraemia AUC (Fig. 2b). There was neither weight loss
(Fig. 2c) nor mortality (Fig. 2d) in these vaccinated animals. How-
ever, animals with lower DN-2 vaccine burden showed a four-fold or
greater boost in post-challenge antibody titres (Fig. 2e). Animals
with higher DN-2 burden did not show such a similar post-challenge
antibody titre boost (Fig. 2e). The post-challenge boost in neutralis-
ing antibody titres thus suggests a loss in sterilising immunity in ani-
mals with reduced DN-2 burden. However, we were unable to detect
wild-type ZIKV infection in the brain, testes, liver, kidneys, epididy-
mis, and eyes of these animals (Supplementary Figure 2) [28].
3.3. Gene expression signatures in peripheral blood mononuclear cells
(PBMCs) suggests that sterilising immunity against ZIKV requires both
humoral and cellular immunity
To explore the possibility of sub-detectable infection in animals
with reduced vaccine burden, we profiled the gene expression in
peripheral blood mononuclear cells (PBMCs) of these animals col-
lected on days 1 and 3 post-challenge. Expression of immune genes
was quantified using the NanoString nCounter Mouse Immunology
panel. Spearman correlation analysis was used to identify genes sig-
nificantly correlated with the magnitude of post-challenge neutralis-
ing antibody titre boost. Expectedly, Gene ontology (GO) enrichment
analysis highlighted STAT phosphorylation and B cell development as
the top pathways positively correlated with neutralising antibody
boost (Fig. 3a), at both days 1 (Fig. 3b and 3c) and 3 post challenge
(Supplementary Figure 3a and 3b). The transcriptional changes are
thus consistent with the notion of subclinical infection in these ani-
mals. Conversely, in animals without boost in antibody titres follow-
ing wild-type ZIKV challenge, the top expressed pathways were
granulocyte recruitment and T cell proliferation (Fig. 3d). Level of
expression of key genes in these pathways at both days 1 (Figs. 3e
and 3f) and 3 (Supplementary Figure 3c and 3d) post challenge were
also significantly and negatively correlated with antibody-fold
change (Figs. 3e and 3f). Indeed, CD81 and Ceacam1 (Fig. 3f) have
been previously shown as important co-stimulatory and proliferation
markers, respectively, of CD8+ T cells [2931]. These findings suggest
that CD8+ T cell immunity may be needed to complement B cell
immunity, despite maximal DN-2 vaccine burden-induced neutralis-
ing antibody titres.
3.4. CD8+ t cells are crucial for the complete clearance of ZIKV infection
in the testes and epididymis of mice
To test the possibility that sterilising immunity in animals with
maximal DN-2 vaccine burden induced neutralising antibody
responses required CD8+ T cell responses, we included selective CD8+
T cell depletion into our animal model. We utilized anti-CD8a mono-
clonal antibodies (i.p.) to selectively deplete the CD8+ lymphocyte
population in ZIKV DN-2 vaccinated A129 mice (without any burden
truncation) before wild-type ZIKV challenge (Fig. 4a) [20]. A corre-
sponding IgG2b isotype antibody was used as a control in a separate
group of animals. An optimal dosage of 10mg of anti-CD8a monoclo-
nal antibody for CD8+ depletion was determined through a series of
titrations (Supplementary Figure 4a). Flow cytometric analysis of
Fig. 1. Truncation of DN-2 burden using a monoclonal antibody treatment reduced anti-ZIKV neutralising antibody titres without affecting CD8+ T cell responses. (a) Experimental
layout of vaccine burden truncation of A129 mice vaccinated with 104 pfu of DN-2 (i.p.) using 10mg/kg of ZAb_FLEP (i.p.). Serum extracted from submandibular blood was quanti-
fied via plaque assay (b) and qRT-PCR (c) for ZIKV infectious particles and genomic copies respectively. Dotted lines indicate limits of detection. (d) ZIKV RNAemia area under the
curve (AUC) was significantly lower in animals administered with ZAb_FLEP on day 3 post-vaccination. (e) Neutralising antibody titres measured on day 21 post-vaccination were
significantly lower in animals administered ZAb_FLEP on day 3 post-vaccination. (f) Anti-ZIKV IgG titres in serum measured on day 21 post-vaccination via ELISA show no differen-
ces despite truncation of DN-2 burden. (g-h) Central memory CD8+ T cells denoted by CD3+/CD8+/CD44+/CD62L+ expression (g) and effector memory CD8+ T cells denoted by CD3+/
CD8+/CD44+/CD62Lexpression (h) were quantified via flow cytometry analysis of splenocytes harvested 21 days post-vaccination. (i) CD8+ cells magnetically isolated from spleno-
cytes harvested 21 days post-vaccination were stimulated with the ZIKV Env294302 peptide and stained for IFNg-producing cells. Two independent experiments were performed
with five animals in each group. One flow cytometry data point from the day 3 cohort was excluded due to poor sample quality. Data are presented as mean§SD. Statistical analyses
were performed using the unpaired t-test. *p 0.05, **p 0.01 and ****p 0.0001.
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Fig. 2. Truncation of DN-2 burden resulted in loss of sterilising immunity upon wild-type challenge. (a) Experimental layout of vaccine burden truncation using 10mg/kg ZAb_FLEP
(i.p.) in A129 mice vaccinated with 104 pfu of DN-2 and subsequent challenge with 104 pfu of H/PF/2013 (i.p.). (b) ZIKV genomic copies were quantified using qRT-PCR on serum
extracted from submandibular blood. The dotted line indicates limit of detection. Mice were (c) weighed daily post-challenge and (d) survival was tracked to 15 days post-chal-
lenge. (e) Neutralising antibody titres were quantified from serum obtained pre-challenge and 15 days post-challenge via plaque reduction neutralization tests (PRNT) to obtain
neutralising antibody titre fold-change. Two independent experiments were performed with five animals in each group. Data are presented as mean§SD. Statistical analysis was
performed using unpaired t-test. *p 0.05.
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before wild-type ZIKV challenge revealed significant ablation of the
CD3+/CD8+lymphocyte population (Fig. 4b). Total B cells and pre-
challenge neutralising antibody titres were unaffected with CD8+ T
cell depletion (Supplementary Figure 4b, 4c and 4d). Upon challenge,
all mice remained healthy with no detectable ZIKV RNAemia (Supple-
mentary Figure 4e and 4f). However, at the point of experiment ter-
mination on day 15 post-challenge, RT-PCR revealed wild-type ZIKV
infection in several organs of CD8-depleted animals. While the brain
and eyes tested negative (Fig. 4c and 4d), two out of the five animals
showed detectable wild-type ZIKV in the livers and kidneys, although
the rate of infection was not statistically significant compared to con-
trols (Figs. 4e and 4f). In the testes and epididymis, however, 4 out of
the 5 (80%) and all 5 (100%) CD8+-depleted mice, respectively,
tested positive for wild-type ZIKV (Fig. 4g and 4h); none of the
control mice showed infection in these same organs. Moreover,
inflammatory genes showed upregulated expression in infected
compared to uninfected testes, suggesting that the RT-PCRpositive findings were not due to virus deposition but rather
infection that stimulated inflammation. Consistent with this
notion that the RT-PCR positivity represented a significant patho-
logical finding, no difference in innate immune or inflammatory
responses was found in the brain (Supplementary Figure 4 g and
4 h). These findings indicate that cellular immunity is critical in
complementing baseline neutralising antibodies to prevent wild-
type ZIKV infection and systemic dissemination.
4. Discussion
The development of flaviviral vaccines have relied on empirically
derived strategies that can be challenging and time-consuming. Iden-
tification of determinants of vaccine-mediated immunity and protec-
tion against flaviviruses could allow for improved vaccine
development strategies. Though A129 mice lack type I interferon
receptor and would not elicit the full spectrum of innate immune
response expected in immunocompetent human infection, the
Fig. 3. Gene expression signatures in peripheral blood mononuclear cells (PBMCs) suggests that sterilising immunity against ZIKV requires both humoral and cellular immunity.
Biological pathways (a) positively and (b) negatively correlated with the magnitude of neutralising antibody titre boosts post-challenge based on gene expression counts acquired
through Nanostring analysis of PBMCs harvested 1- and 3-days post-challenge. Significantly correlated genes on day 1 post-challenge from the top positively regulated pathways of
(c) STAT phosphorylation and (d) B cell development and the top negatively regulated pathways of (e) granulocyte migration and (f) T cell proliferation are shown. Significantly
enriched pathways were identified through Fisher’s exact test with False Discovery Rate (FDR) correction. Correlation analysis was performed using Spearman correlation with sig-
nificance defined as p 0.05.
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Fig. 4. CD8+ T cells are crucial for the complete clearance of ZIKV infection in the testes and epididymis of mice. (a) Experimental layout to selectively deplete CD8+cells by adminis-
tering 10mg of 2.43 anti-CD8a monoclonal antibody (i.p.) to A129 mice vaccinated with 104 pfu of DN-2 and subsequently challenged with 104 pfu of H/PF/2013. (b) Flow cytometry
analysis to evaluate depletion of CD8+cells in peripheral blood after anti-CD8a monoclonal antibody treatment of mice. (c-h) Viral loads of organs harvested 15 days post-challenge
assessed by qRT-PCR for (c) brain, (d) kidneys, (e) liver, (f) eyes, (g) testes, and (h) epididymis. Dotted lines indicate limit of detection. One isotype control mouse developed a testic-
ular tumour and was omitted from subsequent analysis of the testes and epididymis. Two independent experiments were performed with five animals in each group. Data are pre-
sented as mean§SD. Statistical analyses were performed using unpaired t tests. *p 0.05 and ****p 0.0001.
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C. Yau et al. / EBioMedicine 61 (2020) 111 9presence of type II IFN receptor allows for T cell signalling to support
the development of adaptive immunity [24,32]. This mouse model
has also been used previously to assess the efficacy of several ZIKV
vaccine candidates [18,3335]. Though findings in animal models
may not fully translate into a human clinical setting, the A129 mouse
model remains the most well-established model for our study.
We have used the attenuated ZIKV DN-2 strain in our investiga-
tion, which we have previously shown that vaccination with DN-2
fully protected A129 mice from wild-type H/PF/2013 ZIKV challenge
[18]. Moreover, DN-2 infection reproducibly elicits viraemia without
producing signs of illness in A129 mice [18]. This property is consis-
tent with the yellow fever vaccine, where vaccine viraemia did not
correlate with vaccine-associated adverse events [36,37]. We were
thus able to explore, without compromising the health of vaccinated
mice before wild-type ZIKV challenge, how the total live vaccine bur-
den impacts immunogenicity and efficacy.
Truncation of DN-2 burden was achieved through administration
of the ZAb_FLEP anti-ZIKV antibody, allowing for investigation of the
impact of live vaccine infection duration without affecting peak vire-
mia. We found that truncation of vaccine and hence antigenic burden,
as reflected by viremia AUC, led to lower levels of neutralising anti-
bodies, despite no difference in overall IgG antibody levels. There is a
possibility that the reduction in neutralizing antibody titres could
have been due to antibody-mediated termination of germinal centres
[38]. However, the high-affinity IgG that is required to disrupt B cell
interactions with follicular dendritic cells should also affect antigens
displayed on classic dendritic cells. As CD8+ T cell responses are unaf-
fected by ZAb_FLEP treatment (Supplementary Figure 1 g), it is more
likely that the observed decrease in neutralizing antibody titres is
due to the truncation of vaccine viraemia. The resultant reduction of
neutralising antibodies proved insufficient to protect against wild-
type ZIKV infection. Upon antigen encounter, B cells likely undergo
extensive proliferation in germinal centres with eventual differentia-
tion into memory or antibody-producing plasma B cells [39,40]. Anti-
gen persistence, such as vaccine viraemia duration, may thus
stimulate greater levels of affinity maturation of virus-specific anti-
bodies and therefore be critical for the production of potent neutral-
ising antibodies [41]. Indeed, a recent study found that the affinity of
neutralising antibodies after YF17D vaccination continued to improve
up to 6 to 9 months post-vaccination [42], suggesting that a relatively
long antigen persistence may be needed in germinal centres for
robust adaptive immunity [43].
That vaccine burden shapes adaptive immunity may also explain
the efficacy of other flaviviral vaccines. Studies on Dengvaxia vacci-
nation have found proportionately more detectable viraemia with
serotype 4 component of the vaccine, followed by serotypes 3, 1 and
2 [44]. Along similar trend, vaccine efficacy was highest against den-
gue virus (DENV) serotype 4, followed by serotypes 3, 1 and 2 [12].
The vaccine efficacy of TAK-003, another tetravalent dengue vaccine
that has completed phase 3 clinical trial and is undergoing long-term
follow up also showed correlation between vaccine burden and effi-
cacy [45,46]. Finally, yellow fever vaccination elicits detectable virae-
mia that lasts for several days in well over 80% of subjects
consistently [17,47]. Consequently, duration of vaccine burden could
be a useful predictor of the quality and durability of immunity.
Our findings also show that sterilising immunity against ZIKV
requires both humoral and cellular immunity. Reduced neutralising
antibody titres, despite unperturbed CD8+ T cell counts, resulted in a
loss of sterilising immunity. On the other hand, CD8+ T cell depletion
resulted in infection and systemic dissemination of wild-type ZIKV
despite unperturbed B cell count and baseline neutralising antibody
titres. To demonstrate the role CD8+ T cells play in sterilising immu-
nity, we have chosen the CD8+ T cell depletion approach instead of
comparing passive serum infusion with adoptive CD8+ T cell transfer
from vaccinated to naïve mice, as has been previously applied to
study immunity against DENV infection [48]. Passive serum infusionlacks memory B cells that would be activated and expand upon anti-
gen encounter. Presence of memory B cell activation that would be
activated upon wild-type virus challenge would more accurately rep-
resent vaccine-induced immunity. The CD8+ T cell depletion follow-
ing live attenuated DN-2 vaccination thus allowed us to glean
insights into the roles that B and CD8+ T cells play, respectively, in
protection against wild-type ZIKV infection.
Our finding showing wild-type infection in testes and epididymis
of CD8+ T cell depleted vaccinated mice is, to the best of our knowl-
edge, unique. CD8+ T cells could also have abrogated systemic spread
of wild-type ZIKV in animals with lowered neutralising antibody
titres through DN-2 viraemia truncation. Furthermore, previous
work suggests that CD8+ T cells may contribute to protection against
congenital ZIKV infection [49]. This finding thus raises a safety con-
cern with Zika vaccines that do not elicit sufficient levels of cellular
immunity. Given that ZIKV can be transmitted through the sexual
route, lack of ZIKV-specific CD8+ T cells could result in silent virus
transmission from vaccinated males to unvaccinated females [50,51].
This risk is especially important as testicular infection can last for
much longer than ZIKV viraemia [52]. Any ZIKV vaccine candidate
must thus be assessed for its ability to confer sterilising immunity,
especially of the reproductive tract. There are currently several ZIKV
vaccine candidates in clinical development, with a plasmid DNA-
launched vaccine and a formalin-inactivated vaccine at the forefront,
having completed Phase I trials [13,14]. Other candidates including
mRNA and recombinant vaccines are in the midst of phase I clinical
trials, having shown promise in preclinical models [5355]. The qual-
ity of cellular immunity engendered by these vaccine candidates
should thus be evaluated before further clinical development.
While CD8+ T cell depletion reduced vaccine-induced protection
against wild-type ZIKV in various organs, sites protected by the tight
blood-brain barrier, namely the brain and the eyes, remained sterile.
This outcome suggest that the type and level of immunity needed to
protect against flaviviral infection is dependant on the anatomy of
infection. Indeed, the brain and eyes are isolated from blood by endo-
thelial cells linked by tight junctions, or the blood-brain barrier (BBB)
[56]. This BBB may lower the immunity threshold needed to protect
against CNS infection. This may explain why inactivated vaccines
against Japanese encephalitis and tick-borne encephalitis have suc-
cessfully prevented central nervous system infections [9,10]. In con-
trast, inactivated vaccines have mostly shown to be less
immunogenic and likely insufficient in protecting against systemic
DENV infection [5759].
In conclusion, our findings show that vaccine burden is an impor-
tant determinant of vaccine immunogenicity and that in the A129
Type I interferon-deficient mouse model, both B and T cell immune
responses are necessary to confer protection against ZIKV infection.Data sharing
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